

Impact Biomedical Inc. (IBO)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001834105

Impact Biomedical Inc.		
IBO; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$17.4M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, thin data, degenerate inputs not computable: short runway, distress, fortress balance sheet	
Inputs computable	6 of 14	
Graded from	filings received through Mar 11, 2026 212 days before the rescans; latest periodic filing 10-Q received Aug 7, 2026	
Last close	\$4.23 2026-10-08; market equity \$456.1M	
Price used in grade	None	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 11, 2026

Biomedical Inc. ("IBO". "Impact", "Impact BioMedical", "we", "us", "our" or the "Company") discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships, and currently trades on the NYSE American under ticker symbol IBO. leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 53.4						
Gross profitability		(2.3%)	32.2%	98.7	372	2025-12-31

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(52.8%)	(6.6%)	8.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 63.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(4.05)	(0.31)	50.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		(5.40x)	(4.51x)	43.8	81	2025-12-31
Current ratio		0.35x	2.96x	95.6	839	2025-12-31
Growth and financing, sleeve percentile 95.6						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 1
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		not computable	2.1%			four annual observations are required; found 3
Net share issuance, one year		792.2%	2.5%	95.6	634	2026-03-06

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 792.2%
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	775.3%	8.0%	100

Distance from 52-week high	(44.8%)	(31.4%)	32
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.02	0.28	15
Sales to price	0.00	0.31	1
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	1.96	(0.14)	100

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$22,633

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$32,000	2025-12-31	2026-03-11	10-K	0001493152-26-009711
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$424,000	2025-12-31	2026-03-11	10-K	0001493152-26-009711
3	assets	us-gaap:Assets	\$17.4M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
4	net income	us-gaap:NetIncomeLoss	-\$11.8M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$1.9M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
6	assets	us-gaap:Assets	\$20.3M	2024-12-31	2026-03-11	10-K	0001493152-26-009711
7	current assets	us-gaap:AssetsCurrent	\$411,000	2025-12-31	2026-03-11	10-K	0001493152-26-009711
8	current liabilities	us-gaap:LiabilitiesCurrent	\$1.2M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$49.5M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
10	operating income	us-gaap:OperatingIncomeLoss	-\$4.3M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
11	book equity	us-gaap:StockholdersEquity	\$12.6M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
12	liabilities	us-gaap:Liabilities	\$1.9M	2025-12-31	2026-03-11	10-K	0001493152-26-009711
13	interest expense	us-gaap:InterestExpense	\$793,000	2025-12-31	2026-03-11	10-K	0001493152-26-009711
14	assets	us-gaap:Assets	\$44.6M	2023-12-31	2025-03-28	10-K	0001641172-25-001199
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	107,821,231	2026-03-06	2026-03-11	10-K	0001493152-26-009711
16	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,085,412	2025-02-26	2025-03-28	10-K	0001641172-25-001199